ストックスクリーナーアプリを入手
62.76
2.56%
-1.53
前日終値:
$64.29
開ける：
$63.38
24時間の取引高:
159.85K
Relative Volume:
0.13
時価総額：
$5.18B
収益：
$900.66M
当期純損益:
$-453.20M
株価収益率:
-10.57
EPS:
-5.94
ネットキャッシュフロー:
$-274.19M
1週間 パフォーマンス:
-8.01%
1か月 パフォーマンス:
-13.43%
6か月 パフォーマンス:
+9.40%
1年 パフォーマンス:
+20.63%
1日の値動き範囲:
$62.27
$64.50
1週間の範囲:
$62.27
$69.43
52週間の値動き範囲:
$35.95
$87.50
Ptc Therapeutics Inc Stock (PTCT) Company Profile
名前
Ptc Therapeutics Inc
セクター
電話
(908) 222-7000
住所
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
62.62 | 5.32B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.38 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
769.92 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
727.71 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.09 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
294.77 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2025-12-01 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-06-17 | 開始されました | Truist | Buy |
| 2025-05-09 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-05-07 | アップグレード | Citigroup | Sell → Neutral |
| 2025-03-11 | アップグレード | BofA Securities | Underperform → Neutral |
| 2025-03-07 | 開始されました | Scotiabank | Sector Perform |
| 2024-12-13 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-09-04 | 開始されました | Robert W. Baird | Outperform |
| 2024-08-26 | 再開されました | UBS | Buy |
| 2024-05-20 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-10-30 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-10-27 | ダウングレード | Citigroup | Neutral → Sell |
| 2023-10-06 | ダウングレード | Truist | Buy → Hold |
| 2023-09-18 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-09-15 | ダウングレード | Raymond James | Outperform → Underperform |
| 2023-03-17 | 開始されました | SVB Securities | Market Perform |
| 2022-12-14 | 開始されました | Goldman | Sell |
| 2022-09-12 | 開始されました | Jefferies | Buy |
| 2022-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-09-01 | 開始されました | Citigroup | Buy |
| 2022-04-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2021-10-18 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-04-26 | 再開されました | Credit Suisse | Neutral |
| 2021-03-29 | アップグレード | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-01-05 | アップグレード | Citigroup | Neutral → Buy |
| 2020-11-30 | ダウングレード | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-10-07 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-04-09 | アップグレード | Citigroup | Neutral → Buy |
| 2020-02-20 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-02-20 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-05-13 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | 開始されました | Bernstein | Outperform |
| 2018-10-03 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-07-19 | 開始されました | Credit Suisse | Outperform |
| 2018-06-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2018-01-29 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | アップグレード | JP Morgan | Underweight → Neutral |
| 2017-10-26 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | ダウングレード | JP Morgan | Neutral → Underweight |
すべてを表示
Ptc Therapeutics Inc (PTCT) 最新ニュース
PTC Therapeutics, Inc. (PTCT) - DirectorsTalk Interviews
Oversold Conditions For PTC Therapeutics (PTCT) - Nasdaq
PTC Therapeutics (PTCT) Gains Edge as Competitor Faces Setback - GuruFocus
PTC Therapeutics Grants Stock Options and RSUs to New Employees - Intellectia AI
Assessing PTC Therapeutics (PTCT) Valuation After Contrasting Quarterly Loss And Full Year Profit Turnaround - Sahm
JPMorgan Chase & Co. Reduces Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics vs Merck: Which Is the Stronger Buy Today? - Trefis
GSA Capital Partners LLP Decreases Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTCT Should I Buy - Intellectia AI
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
16,062 Shares in PTC Therapeutics, Inc. $PTCT Purchased by Private Capital Advisors Inc. - MarketBeat
PTC Therapeutics, Inc. $PTCT Holdings Decreased by Vanguard Group Inc. - MarketBeat
PTC Therapeutics Experiences Revision in Stock Evaluation Amid Mixed Financial Performance - Markets Mojo
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2025 earnings call transcript - MSN
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2025 Earnings Call Transcript - Insider Monkey
PTC Therapeutics outlines 19%-36% 2026 product revenue growth target as Sephience momentum accelerates globally - MSN
How Translarna NDA Withdrawal and Mixed Results Will Impact PTC Therapeutics (PTCT) Investors - Sahm
PTC Therapeutics, Inc. (PTCT) Stock Analysis: Exploring a 24.21% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) VP Sells 3,019 Shares of Stock - MarketBeat
PTC Therapeutics (PTCT) CLO Boulding sells 3,019 shares under 10b5-1 plan - Stock Titan
PTC Therapeutics to Participate at Upcoming Investor Conferences - GuruFocus
Morgan Stanley raises PTC Therapeutics stock price target on OpEx cuts - Investing.com Australia
PTC Therapeutics: Sephience As A Major Growth Driver (NASDAQ:PTCT) - Seeking Alpha
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Takes Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
How Sephience Is Reshaping The Story For PTC Therapeutics (PTCT) And Analyst Expectations - Yahoo Finance
PTC Therapeutics, Inc. $PTCT Shares Sold by Hillsdale Investment Management Inc. - MarketBeat
19,142 Shares in PTC Therapeutics, Inc. $PTCT Acquired by Brummer Multi Strategy AB - MarketBeat
PTC Therapeutics (PTCT) Q4 earnings: Taking a look at key metrics versus estimates - MSN
Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), Guardant Health (GH) and PTC Therapeutics (PTCT) - The Globe and Mail
PTC Therapeutics (NASDAQ:PTCT) Cut to "Hold" at Wall Street Zen - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CAO Sells 2,494 Shares of Stock - MarketBeat
Lee Scott Golden Sells 2,484 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 3,019 Shares of Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Insider Neil Gregory Almstead Sells 3,056 Shares - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) CFO Pierre Gravier Sells 2,992 Shares - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CEO Sells 7,371 Shares of Stock - MarketBeat
PTC’s Sephience Launch Appears Off To A Strong Start - Citeline News & Insights
Cantor Fitzgerald reiterates Overweight on PTC Therapeutics stock By Investing.com - Investing.com Canada
PTC Therapeutics (NASDAQ:PTCT) Trading Down 6.5% on Disappointing Earnings - MarketBeat
PTC Therapeutics (PTCT): RBC Capital Lowers Price Target to $82 - GuruFocus
Bank of America Lowers PTC Therapeutics (NASDAQ:PTCT) Price Target to $93.00 - MarketBeat
B of A Securities Lowers Price Target for PTC Therapeutics (PTCT) to $93 | PTCT Stock News - GuruFocus
PTC Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
PTC Therapeutics Inc (PTCT) Q4 2025 Earnings Call Highlights: Su - GuruFocus
Cantor Fitzgerald Keeps Overweight on PTC Therapeutics (PTCT) Feb 20 2026 - Meyka
PTC Therapeutics exec. VP Boulding sells $408,612 in stock By Investing.com - Investing.com Canada
PTC Therapeutics exec. VP Boulding sells $408,612 in stock - Investing.com Australia
Decoding PTC Therapeutics Inc (PTCT): A Strategic SWOT Insight - GuruFocus
PTC Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
PTC Therapeutics Q4 Earnings Call Highlights - MarketBeat
PTC Therapeutics earnings missed by $1.41, revenue fell short of estimates - Investing.com Canada
Ptc Therapeutics Inc (PTCT) 財務データ
収益
当期純利益
現金流量
EPS
Ptc Therapeutics Inc (PTCT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Utter Christine Marie | SVP, CHIEF ACCOUNTING OFFICER |
Feb 18 '26 |
Sale |
69.36 |
2,494 |
172,984 |
70,199 |
| Gravier Pierre | CHIEF FINANCIAL OFFICER |
Feb 18 '26 |
Sale |
69.36 |
2,992 |
207,525 |
87,318 |
| Pauwels Eric | CHIEF BUSINESS OFFICER |
Feb 18 '26 |
Sale |
69.36 |
3,019 |
209,398 |
77,122 |
| Klein Matthew B. | CHIEF EXECUTIVE OFFICER |
Feb 18 '26 |
Sale |
69.36 |
7,371 |
511,253 |
387,082 |
| Golden Lee Scott | EVP & CHIEF MEDICAL OFFICER |
Feb 18 '26 |
Sale |
69.36 |
2,484 |
172,290 |
89,944 |
| Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER |
Feb 18 '26 |
Sale |
69.36 |
3,056 |
211,964 |
112,140 |
| Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER |
Feb 18 '26 |
Sale |
69.36 |
65 |
4,508 |
6,726 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Feb 17 '26 |
Option Exercise |
25.69 |
2,813 |
72,266 |
114,125 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Feb 18 '26 |
Sale |
69.36 |
3,081 |
213,698 |
108,231 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Feb 17 '26 |
Sale |
69.29 |
2,813 |
194,914 |
111,312 |
0.50%
大文字化:
|
ボリューム (24 時間):